Head-To-Head Survey: ThermoGenesis (THMO) and Its Rivals

ThermoGenesis (NASDAQ:THMO) is one of 144 public companies in the “Medical Devices” industry, but how does it weigh in compared to its competitors? We will compare ThermoGenesis to similar businesses based on the strength of its analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings.

Earnings and Valuation

This table compares ThermoGenesis and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
ThermoGenesis	$9.44 million	-$17.98 million	-0.04
ThermoGenesis Competitors	$535.59 million	$9.82 million	154.56

ThermoGenesis’ competitors have higher revenue and earnings than ThermoGenesis. ThermoGenesis is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares ThermoGenesis and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ThermoGenesis	-153.43%	-4,838.39%	-107.53%
ThermoGenesis Competitors	-71.34%	-134.76%	-19.04%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for ThermoGenesis and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ThermoGenesis	0	0	1	0	3.00
ThermoGenesis Competitors	297	1356	1536	41	2.41

ThermoGenesis presently has a consensus price target of $5.00, suggesting a potential upside of 2,400.00%. As a group, “Medical Devices” companies have a potential upside of 218.26%. Given ThermoGenesis’ stronger consensus rating and higher possible upside, equities analysts clearly believe ThermoGenesis is more favorable than its competitors.

Insider and Institutional Ownership

5.8% of ThermoGenesis shares are owned by institutional investors. Comparatively, 28.8% of shares of all “Medical Devices” companies are owned by institutional investors. 78.0% of ThermoGenesis shares are owned by company insiders. Comparatively, 25.3% of shares of all “Medical Devices” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk and Volatility

ThermoGenesis has a beta of 2.31, suggesting that its stock price is 131% more volatile than the S&P 500. Comparatively, ThermoGenesis’ competitors have a beta of 0.93, suggesting that their average stock price is 7% less volatile than the S&P 500.

Summary

ThermoGenesis competitors beat ThermoGenesis on 8 of the 13 factors compared.

ThermoGenesis Company Profile

ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics in the United States, China, the United Arab Emirates, Vietnam, and internationally. The company provides medical device products for automated cell processing. Its clinical bio-banking applications include AXP II Automated Cell Separation System, an automated fully closed cell separation system for isolating stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. The company’s point-of-care applications include XP Point-of-Care System, an automated, fully closed, sterile system that allows for the rapid and automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; and PXP-1000 System, an automated, fully closed system that provides fast, reproducible separation of multiple cellular components from blood with minimal red blood cell contamination. Its cell processing products comprise X-Series products for general laboratory use, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, and X-Mini for high efficiency small scale cell purification. The company also provides contract development and manufacturing services for cell and cell-based gene therapies. It markets and sells its medical device products through independent distributors, as well as direct to end-user customers. The company was formerly known as Cesca Therapeutics Inc. and changed its name to ThermoGenesis Holdings, Inc. in November 2019. ThermoGenesis Holdings, Inc. was incorporated in 1986 and is headquartered in Rancho Cordova, California.